Introduction

Actiza Pharmaceutical is a WHO-GMP certified pharmaceutical exporter supplying Nitrofurantoin Capsules as a finished dosage formulation not API to importers, distributors and hospital procurement across Africa, Southeast Asia, Latin America and the Middle East.

We supply both registered presentations: nitrofurantoin macrocrystals and nitrofurantoin monohydrate/macrocrystals, which are distinct formulations with separate reference products and separate bioequivalence requirements.

Nitrofurantoin remains widely used for uncomplicated lower urinary tract infection, where its narrow tissue distribution is a stewardship advantage rather than a limitation.

Complete CTD, ACTD and eCTD dossiers, in-vivo bioequivalence data, CoPP, FSC and ICH Zone IVb stability are supplied for MOH registration.

Product Overview Table

Field	Details
Product Name	Nitrofurantoin Capsules
INN / Generic Name	Nitrofurantoin
Therapeutic Class	Nitrofuran antibacterial urinary tract anti-infective
Presentations	Two distinct products: nitrofurantoin macrocrystals, and nitrofurantoin monohydrate/macrocrystals. Not interchangeable
Indication	Urinary tract infection, per approved local labelling. Narrow tissue distribution not for systemic infection.
API Quality	Manufactured using DMF-grade Nitrofurantoin
Pharmacopoeial Standard	USP Nitrofurantoin Capsules USP; separate monograph applies to the monohydrate/macrocrystals presentation
Available Strengths	Macrocrystals: 25 mg, 50 mg, 100 mg. Monohydrate/macrocrystals: 100 mg.
Contraindicated Renal	Anuria, oliguria, or significant renal impairment (creatinine clearance under 60 mL/min, or clinically significant elevated serum creatinine)
Contraindicated Obstetric	Pregnant patients at term (38 to 42 weeks gestation), during labour and delivery, or when onset of labour is imminent
Key Warning G6PD	Haemolytic anaemia of the primaquine-sensitivity type has been induced. Haemolysis is linked to glucose-6-phosphate dehydrogenase deficiency.
Other Major Warnings	Acute, subacute and chronic pulmonary reactions; hepatic reactions; peripheral neuropathy, which may be severe or irreversible; optic neuritis reported rarely
Critical Quality Attribute	Crystal form and particle size distribution these govern dissolution, absorption and gastrointestinal tolerability
Administration	With food, per approved labelling improves absorption and tolerability
Patient Counselling Point	Urine may become dark yellow or brown harmless, but patients stop therapy over it if not forewarned
Shelf Life	36 Months
Storage	Protect from light and moisture
Manufacturing Facility	WHO-GMP certified general oral solid dosage block, segregated from beta-lactam operations
Dossier Available	Yes, CTD / ACTD / eCTD format

The Two Presentations, and Why the Difference Matters

Nitrofurantoin Macrocrystals Capsules

The original macrocrystalline presentation, supplied in 25 mg, 50 mg and 100 mg capsules.

The macrocrystal form exists for a specific reason: larger crystals dissolve more slowly than microcrystalline nitrofurantoin, which moderates the rate of absorption and materially improves gastrointestinal tolerability.

Nausea is the principal reason patients abandon nitrofurantoin therapy, so the crystal size is not a manufacturing detail it is the property that determines whether a course gets completed.

Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg

A distinct product, not a variant. This presentation combines nitrofurantoin monohydrate with macrocrystals in a single capsule, producing a different release and absorption profile and a different approved dosing regimen from the macrocrystals presentation.

It has its own reference product, its own pharmacopoeial monograph and its own bioequivalence requirement.

Reference labelling for this presentation also notes that lower eradication rates should be weighed against the greater systemic toxicity and resistance potential of agents with broader tissue distribution a framing worth understanding before positioning the product.

Why This Distinction Costs Money If Missed

Different reference products means different comparator sourcing for bioequivalence studies

Different pharmacopoeial monographs apply confirm which governs your SKU before fixing the specification

Artwork must state the presentation explicitly, not merely “Nitrofurantoin Capsules 100 mg”

Specification & Testing

Crystal form and particle size distribution are the governing quality attributes and are specified explicitly, not inherited from the API supplier’s certificate

Discriminatory dissolution method validated across the physiological pH range nitrofurantoin is poorly soluble and dissolution governs both absorption and tolerability

Assay, content uniformity and related substances against the declared monograph

Photostability and moisture control across shelf life nitrofurantoin is light-sensitive and the capsule shell does not protect it once the blister is opened

Regulatory & Dossier Support

Dossier Availability

CTD (Common Technical Document): ICH-aligned, for regulated and semi-regulated markets

ACTD (ASEAN Common Technical Dossier): Philippines, Vietnam, Myanmar, Indonesia, Cambodia

eCTD: for authorities mandating electronic submission

Module 3 quality documentation including crystal form and particle size specification, process validation, dissolution method validation and photostability

Stability data: real-time and accelerated under ICH Zone IVb (30°C / 75% RH)

Separate dossiers maintained for the macrocrystals and monohydrate/macrocrystals presentations they are not variants of one submission

Bioequivalence Poorly Soluble, and Form-Specific

Nitrofurantoin is poorly water-soluble, so dissolution rather than assay governs absorption and a BCS-based biowaiver is not available.

In-vivo bioequivalence (BE) data against the reference product is required.

The point that trips applicants up is which reference: the macrocrystals and monohydrate/macrocrystals presentations have separate reference products, and a study conducted against the wrong one cannot support the registration regardless of how well it was executed.

Particle size distribution is the formulation variable that decides the outcome.

Because crystal size controls dissolution rate, a formulation matched on assay but not on particle size will not be bioequivalent this is the nitrofurantoin equivalent of the excipient-system point on the Cyclophosphamide page

Discriminatory dissolution method documented and validated, with profiles held throughout shelf life

Where an authority accepts a strength biowaiver within the macrocrystals range, proportional similarity and comparable dissolution must be demonstrated subject to the individual authority

Drug Master File

Drug Master File (DMF) reference for the Nitrofurantoin API available for cross-referencing in your registration dossier

API sourced against a qualified vendor with impurity, residual solvent and critically crystal form and particle size distribution characterisation

CDSCO / Indian DMF reference accepted by a large number of importing authorities

Manufacturing Compliance

WHO-GMP certified manufacturing facility, audit-ready, with inspection reports shared on an NDA basis

Site Master File (SMF) available for regulatory submissions

Nitrofurantoin is not a beta-lactam and is not a cytotoxic, so no dedicated block is required.

Production runs in a general oral solid dosage block physically segregated from beta-lactam operations, with validated cleaning between products

Particle size is protected through the process, not only at intake.

Milling, blending and encapsulation are controlled so that the crystal size distribution specified for the product is what actually reaches the capsule attrition during processing is a real failure mode on a macrocrystalline product

Light-protected handling through manufacture and packing, consistent with the photostability profile

Compliant with the requirements of NAFDAC (Nigeria), PPB (Kenya), FDA Philippines, DRAP (Pakistan) and INVIMA (Colombia)

Complete Documentation Package

Document	Purpose
Certificate of Analysis (CoA)	Confirms batch quality against the agreed specification
Certificate of Pharmaceutical Product (CoPP / CPP)	Required for MOH registration in most importing countries
Free Sale Certificate (FSC)	Confirms the product is freely sold in the country of manufacture
Method of Analysis (MOA)	Analytical methodology mandatory dossier component
GMP Certificate	Confirms manufacturing site compliance
Stability Data	Real-time and accelerated ICH Zone IVb, plus photostability
BE Study Report	States explicitly which presentation and which reference product it covers
Particle Size Distribution Data	Batch-level the governing quality attribute on this molecule
Dissolution Profile Report	Discriminatory method across the physiological pH range
Presentation Declaration	States unambiguously whether the batch is macrocrystals or monohydrate/macrocrystals
Excipient Declarations	For all inactive ingredients, including capsule shell origin
BSE/TSE Declaration	For gelatin capsule shells; HPMC alternative available

G6PD Deficiency Why This Warning Matters More in These Markets

The practical consequence is that leaflet content and prescriber information on this product should not simply be transcribed from a reference label written for a different population.

The G6PD warning deserves prominence proportionate to local prevalence, and the accompanying instruction is straightforward: haemolysis is an indication for discontinuing nitrofurantoin, and it ceases when the drug is withdrawn.

We carry the G6PD warning prominently rather than burying it in a general haematological reactions list, and we recommend buyers raise its placement with their regulatory authority rather than defaulting to reference-label layout

The obstetric contraindication is connected and equally market-relevant.

The product is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labour and delivery, and where onset of labour is imminent, because of the possibility of haemolytic anaemia arising from immature erythrocyte enzyme systems

The renal contraindication is the other one buyers underestimate. Anuria, oliguria and significant renal impairment creatinine clearance under 60 mL per minute, or clinically significant elevated serum creatinine are contraindications, because impaired excretion increases toxicity risk.

In markets with a high burden of undiagnosed renal disease, that is a meaningful prescribing constraint

Peripheral neuropathy risk is amplified by conditions common in these markets.

Reference labelling notes that renal impairment, anaemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency and debilitating disease may enhance its occurrence, and the neuropathy may be severe or irreversible

Pulmonary and hepatic reactions matter most in prophylactic use.

Where the product is used long term at low dose for recurrent infection, the chronic pulmonary and hepatic warnings become the governing safety consideration rather than a background caution

We supply the full warning set translated for the destination market, and we will not abbreviate the haematological, pulmonary, hepatic or neuropathy sections to fit a smaller leaflet format

Clinical Indications & Therapeutic Information

Nitrofurantoin is a nitrofuran antibacterial concentrated in the urine, where it achieves therapeutic levels while systemic tissue concentrations remain low.

That narrow distribution defines both its use and its limits.

Approved indication: urinary tract infection, per approved local labelling.

It is not appropriate for systemic infection, and reference labelling directs that where bacteriuria persists or reappears after treatment, agents with broader tissue distribution should be selected

The narrow distribution is a stewardship advantage.

Reference labelling frames the trade-off explicitly: lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when broader-spectrum agents are used instead.

In a period of intensifying stewardship pressure, that argument runs in this molecule’s favour

Administration is with food per approved labelling, which improves both absorption and gastrointestinal tolerability

Patients should be told that urine may turn dark yellow or brown.

It is harmless, but patients who are not forewarned discontinue therapy over it a small counselling point with a measurable effect on course completion

Market structure: urinary tract infection is among the most common bacterial infections presented in primary care across every market this page targets, and nitrofurantoin has retained useful activity where broader-spectrum oral agents have lost it.

Volumes are high, tender-driven and stable, so the differentiators are documentation quality, correct presentation identification and supply reliability

Target Export Markets

Africa

Active markets: Nigeria, Kenya, Ghana, Egypt, Tanzania, Uganda, Ethiopia, Zambia, Côte d’Ivoire

Registration support: NAFDAC (Nigeria), PPB (Kenya), FDA Ghana, TFDA (Tanzania) CoPP and FSC are the primary gatekeeping documents

Leaflet emphasis note: G6PD deficiency prevalence is materially higher across this region than in the markets where reference labelling originated.

Labelling: English and French artwork available for Anglophone and Francophone Africa

Southeast Asia

Active markets: Philippines, Vietnam, Myanmar, Cambodia, Indonesia, Bangladesh, Thailand

ACTD dossier format supplied as standard mandatory for ASEAN registrations

Stability: ICH Zone IVb data is a prerequisite, and moisture protection matters given the photostability and moisture sensitivity of the molecule

Latin America (LATAM)

Active markets: Colombia, Peru, Ecuador, Bolivia, Guatemala, Dominican Republic

USP pharmacopoeial standard preferred; Spanish and Portuguese labelling available

CTD format with local regulatory adaptation, legalisation and apostille support

Middle East & CIS

Active markets: Iraq, Jordan, Yemen, Uzbekistan, Kazakhstan, Azerbaijan

GMP Certificate and CoPP are the primary registration requirements across these authorities

Export Packaging & Supply Chain

Primary Packaging Options

Presentation	Packaging Options
Nitrofurantoin Macrocrystals 50 mg / 100 mg	Alu-Alu blister 10×10 and 2×10, light and moisture protective, in mono-carton with leaflet
Nitrofurantoin Macrocrystals 25 mg	Alu-Alu blister 10×10; supports lower-dose prophylactic regimens
Nitrofurantoin Monohydrate/Macrocrystals 100 mg	Alu-Alu blister 2×10 and 1×14, aligned to a treatment course
Course packs	Configurations matching the approved course length, so a patient receives a complete course

Alu-Alu is specified rather than offered as an upgrade.

Nitrofurantoin is light-sensitive and moisture-sensitive, and a capsule shell provides no protection once the primary pack is breached.

Course-matched packs deserve serious consideration on an antibacterial: a patient dispensed a partial course is the mechanism by which resistance develops, and pack size is one of the few levers a manufacturer actually controls.

Labelling & Customisation

Private label manufacturing with your brand name and artwork, subject to unchanged regulatory content

Multi-lingual labelling: English, French, Spanish, Portuguese, Arabic, Russian

Mandatory artwork content: the presentation stated explicitly (macrocrystals or monohydrate/macrocrystals), the G6PD and haematological warnings, the renal and obstetric contraindications, the take-with-food instruction, the urine discolouration note, storage statement and country-specific registration fields

Logistics & Supply

Incoterms: FOB, CIF, CFR, EXW as per buyer requirement

No cold chain required; protect from light, moisture and sustained heat in transit

High-volume primary care line: we plan against committed annual forecasts, and we hold the two presentations as separate stock lines rather than treating them as interchangeable inventory

Why Source Nitrofurantoin Capsules From Us?

We Ask Which Presentation Before We Quote: Macrocrystals and monohydrate/macrocrystals are different products with different reference products, dosing regimens and bioequivalence requirements.

We establish which you need first, which prevents the single most expensive error on this molecule.

Particle Size Controlled as a Critical Quality Attribute: Crystal size governs dissolution, absorption and gastrointestinal tolerability. We specify it explicitly and protect it through milling, blending and encapsulation rather than accepting whatever survives processing.

G6PD Warning Given the Prominence These Markets Require: Reference labelling notes this deficiency in around 10 percent of Black patients and in Mediterranean and Near-Eastern populations. We carry the warning prominently rather than transcribing a layout designed for a different population.

Both Dossiers Maintained Separately: CTD, ACTD and eCTD for each presentation, with the bioequivalence study stating explicitly which reference product it covers.

Course-Matched Pack Options: Partial courses drive resistance, and pack size is one of the few levers a manufacturer controls. We will configure to the approved course length rather than to a round number.

WHO-GMP Certified Manufacturing: Segregated general oral solid facility with validated cleaning and light-protected handling. GMP certificate and Site Master File (SMF) shared on request.

Frequently Asked Questions

Ready to Source Nitrofurantoin Capsules FDF?

Tell us your target market and which presentation your registered reference product is macrocrystals or monohydrate/macrocrystals and our export team will confirm the applicable dossier, specification, bioequivalence position, pack options and pricing.

If you are unsure which applies, send us the reference product details and we will identify it for you before anything is quoted.